VIATRIS INC. Restructuring and Related Cost, Incurred Cost
VIATRIS INC. (VTRS) reported Restructuring and Related Cost, Incurred Cost of $4.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2026-08-06
- VIATRIS INC. restructuring and related cost, incurred cost for the quarter ending 2026-06-30 was $4.40M.
- VIATRIS INC. restructuring and related cost, incurred cost for the quarter ending 2026-03-31 was $2.10M.
- VIATRIS INC. restructuring and related cost, incurred cost for the quarter ending 2023-09-30 was $6.30M, a 43.24% decline year-over-year.
- VIATRIS INC. restructuring and related cost, incurred cost for the quarter ending 2023-06-30 was $77.30M, a 1882.05% increase year-over-year.
- VIATRIS INC. restructuring and related cost, incurred cost for fiscal 2021 was -$32.90M.
- VIATRIS INC. restructuring and related cost, incurred cost for fiscal 2020 was -$32.90M.
- VIATRIS INC. restructuring and related cost, incurred cost for fiscal 2019 was -$78.30M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.40M 10-Q · filed 2026-08-06 | $6.50M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.10M 10-Q · filed 2026-08-06 | |||
| 2023-09-30 | $6.30M 10-Q · filed 2023-11-08 | $83.60M derived: sum of 2 quarters · filed 2023-11-08 | $87.40M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2023-06-30 | $77.30M 10-Q · filed 2023-11-08 | $81.10M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2023-03-31 | $3.80M 10-Q · filed 2023-11-08 | |||
| 2022-09-30 | $11.10M 10-Q · filed 2022-11-07 | $15.00M derived: sum of 2 quarters · filed 2022-11-07 | $19.20M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2022-06-30 | $3.90M 10-Q · filed 2022-11-07 | $8.10M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2022-03-31 | $4.20M 10-Q · filed 2022-11-07 | |||
| 2021-12-31 | -$32.90M 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $87.30M 10-Q · filed 2021-11-08 | $168.10M derived: sum of 2 quarters · filed 2021-11-08 | $319.10M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2021-06-30 | $80.80M 10-Q · filed 2021-11-08 | $231.80M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2021-03-31 | $151.00M 10-Q · filed 2021-11-08 | |||
| 2020-12-31 | -$32.90M 10-K · filed 2022-02-28 | |||
| 2019-12-31 | -$78.30M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |